Vanguard Group Inc. Has $61.52 Million Stock Holdings in Janux Therapeutics, Inc. $JANX

Vanguard Group Inc. grew its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 6.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,278,660 shares of the company's stock after purchasing an additional 142,328 shares during the quarter. Vanguard Group Inc. owned about 3.85% of Janux Therapeutics worth $61,524,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in JANX. GAMMA Investing LLC grew its stake in shares of Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock valued at $45,000 after buying an additional 1,574 shares during the period. US Bancorp DE grew its stake in shares of Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company's stock valued at $47,000 after buying an additional 1,658 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Janux Therapeutics in the 4th quarter valued at about $59,000. Finally, FNY Investment Advisers LLC grew its stake in shares of Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock valued at $66,000 after buying an additional 2,425 shares during the period. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $24.30 on Monday. Janux Therapeutics, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $71.71. The stock has a market cap of $1.46 billion, a PE ratio of -13.50 and a beta of 2.86. The firm's 50-day simple moving average is $24.51 and its 200 day simple moving average is $27.58.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.07). As a group, analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Piper Sandler assumed coverage on Janux Therapeutics in a research note on Monday, August 18th. They issued an "overweight" rating and a $42.00 target price for the company. Raymond James Financial assumed coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $86.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.